Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 171.65M | 177.50M | 176.99M | 169.49M | 162.79M |
| Gross Profit | -171.65M | -177.50M | -176.99M | -169.49M | -162.79M |
| SG&A Expenses | 47.91M | 46.15M | 45.15M | 44.87M | 45.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.56M | 223.64M | 222.15M | 214.36M | 208.57M |
| Operating Income | -219.56M | -223.64M | -222.15M | -214.36M | -208.57M |
| Income Before Tax | -155.22M | -148.98M | -206.81M | -208.93M | -207.97M |
| Income Tax Expenses | -15.00K | -14.00K | 4.00K | 4.00K | 51.00K |
| Earnings from Continuing Operations | -155.20 | -148.97 | -206.81 | -208.93 | -208.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -155.20M | -148.97M | -206.81M | -208.93M | -208.02M |
| EBIT | -219.56M | -223.64M | -222.15M | -214.36M | -208.57M |
| EBITDA | -- | -61.07M | -116.27M | -160.23M | -207.82M |
| EPS Basic | -1.93 | -2.03 | -2.94 | -3.01 | -3.14 |
| Normalized Basic EPS | -1.58 | -1.70 | -2.43 | -2.48 | -2.77 |
| EPS Diluted | -1.93 | -2.03 | -2.94 | -3.01 | -3.14 |
| Normalized Diluted EPS | -1.58 | -1.70 | -2.43 | -2.48 | -2.77 |
| Average Basic Shares Outstanding | 256.10M | 236.27M | 226.75M | 211.80M | 188.05M |
| Average Diluted Shares Outstanding | 256.10M | 236.27M | 226.75M | 211.80M | 188.05M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |